Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E77.45 EPS (ttm)0.93 Insider Own0.10% Shs Outstand1.67B Perf Week2.12%
Market Cap120.54B Forward P/E23.79 EPS next Y3.03 Insider Trans-7.25% Shs Float1.67B Perf Month12.99%
Income1.57B PEG3.66 EPS next Q0.64 Inst Own74.30% Short Float1.33% Perf Quarter16.81%
Sales16.56B P/S7.28 EPS this Y-22.30% Inst Trans0.08% Short Ratio3.45 Perf Half Y8.02%
Book/sh8.54 P/B8.45 EPS next Y26.57% ROA4.90% Target Price71.59 Perf Year15.93%
Cash/sh2.56 P/C28.23 EPS next 5Y21.16% ROE10.40% 52W Range50.91 - 73.06 Perf YTD5.55%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI3.90% 52W High-1.20% Beta0.52
Dividend %2.11% Quick Ratio1.10 Sales past 5Y-3.20% Gross Margin76.90% 52W Low41.78% ATR1.37
Employees25000 Current Ratio1.30 Sales Q/Q0.70% Oper. Margin7.60% RSI (14)77.49 Volatility2.58% 2.00%
OptionableYes Debt/Eq0.47 EPS Q/Q- Profit Margin9.50% Rel Volume1.48 Prev Close72.26
ShortableYes LT Debt/Eq0.46 EarningsApr 28 BMO Payout158.40% Avg Volume6.44M Price72.18
Recom2.40 SMA205.86% SMA5010.64% SMA20013.18% Volume9,503,240 Change-0.11%
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-28-16 06:39PM  Cramer: Raging bull market brewing for pharma at CNBC
06:25PM  Cramer: Raging bull market brewing for pharma CNBC
03:20PM  Edited Transcript of BMY earnings conference call or presentation 28-Apr-16 2:30pm GMT Thomson Reuters StreetEvents
01:25PM  Bristol-Myers (BMY) Stock Climbs on Q1 Earnings, Revenue Beat at TheStreet
01:17PM  Bristol raises 2016 forecast after earnings beat Reuters
01:07PM  Bristol-Myers Hits 17-Year High On Q1 Report; Celgene Also Up at Investor's Business Daily
12:48PM  Today's buzz on the NYSE trading floor was clearly: "take 'em" Yahoo Finance
11:58AM  Heres Why Investors Are Watching These Five Stocks Today at Insider Monkey
11:27AM  Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View Zacks
11:22AM  Facebook hits new high; DreamWorks' $3.8 billion deal; Amazon results on tap Yahoo Finance
09:20AM  Bristol-Myers Squibb Offers Up Solid Earnings Beat and Lifts Guidance at 24/7 Wall St.
09:08AM  How Bristol-Myers Squibb (BMY) Stock Stands Out in a Strong Industry Zacks
08:27AM  Bristol-Myers (BMY) Beats on Q1 Earnings and Revenues Zacks
08:18AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E EDGAR Online
07:21AM  Bristol-Myers tops Street 1Q forecasts AP
07:07AM  Q1 2016 Bristol-Myers Squibb Co Earnings Release - Before Market Open CCBN
07:03AM  Bristol-Myers Profit Beats Expectations, 2016 Guidance Raised at Bloomberg
07:00AM  Bristol-Myers 1Q sales jump but costs keep its profit flat AP
06:59AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
06:59AM  Bristol raises 2016 forecast after first-quarter earnings beat Reuters
06:59AM  [$$] Bristol-Myers Revenue Rises 8.7%, at The Wall Street Journal
Apr-27-16 12:52PM  How Will Bristol-Myers (BMY) Stock React to Tomorrow's Q1 Earnings? at TheStreet
10:00AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference Business Wire
Apr-26-16 03:21PM  3 Stocks Any Investor Can Buy at Motley Fool
03:00PM  Exelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin! at Motley Fool
08:00AM  New ranking crowns JPMorgan the top US company for diversity and inclusion at CNBC
07:27AM  [$$] Allied Minds Supports Bristol-Myers Partnership With $80M Fund at The Wall Street Journal
Apr-25-16 12:57PM  Busiest earnings week of the quarter CNBC
07:10AM  Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings at TheStreet
07:08AM  Big Drug Stocks to Report This Week: LLY, GSK, VRTX, BMY, ABBV Zacks
06:59AM  Bristol-Myers Squibbs Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Business Wire
Apr-22-16 12:31PM  Bristol-Myers (BMY) Q1 Earnings: Can the Stock Surprise? Zacks
Apr-21-16 12:41PM  3 Dividend Stocks for Retirees at Motley Fool
09:59AM  Moving Average Crossover Alert: Bristol-Myers (BMY) Zacks
09:00AM  How These Drug Manufacturers BMY, LLY, AZN, and GSK are Performing Accesswire
Apr-20-16 06:05PM  Is Sanofi Trying to Acquire Medivation? Market Realist
Apr-19-16 01:22PM  [$$] Roche 'very optimistic' on prospects for new cancer drugs at Financial Times
09:30AM  Bristol-Myers' Opdivo extends survival in head and neck cancer -study Reuters
09:30AM  First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigators Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Business Wire
09:30AM  Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer at Bloomberg
Apr-18-16 03:00PM  Drug giant plots Peninsula expansion, 150 more jobs at bizjournals.com
09:41AM  5 Stocks to Supplement Your Social Security Benefits at Motley Fool
Apr-17-16 03:15PM  First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma Business Wire
Apr-16-16 11:41AM  The Big Downside to Better Medicine? Higher Prices at Motley Fool
Apr-15-16 01:25PM  Lessons for Theranos: Patients matter more than disruption at bizjournals.com
11:22AM  [$$] Best Bets in Biopharma at Barrons.com
08:49AM  EU extends safety review of chronic Hep C treatments Reuters
05:57AM  Low Expectations Could Yield Positive Surprises
Apr-14-16 05:45PM  New tests for choosing right hep C drug could save money
04:30PM  Stand Up To Cancer launches new industry-supported research program at bizjournals.com
08:49AM  [$$] FDA to Review Bristol-Myers's Opdivo for Hodgkin Lymphoma at The Wall Street Journal
06:59AM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients Business Wire
05:19AM  [$$] China to punish officials in vaccine scandal at Financial Times
Apr-13-16 04:57PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today at Motley Fool
03:53PM  [$$] A Perfect Climate for Bond-Like Stocks at Barrons.com
03:39PM  3 Biotech Takeover Targets That Could Get Bought Soon at Motley Fool
09:07AM  IBB Large-Caps: Mylan Launches Generic Version of Lopressor
Apr-12-16 03:49PM  Genentech moves to drug-approval fast lane as immunotherapy speeds up at bizjournals.com
10:01AM  Goldman's Kostin: Dollar, oil & financials trouble for ma...
08:10AM  3 Nominations for Big Pharma's Riskiest Pipeline -- and Why They Qualify at Motley Fool
Apr-11-16 10:01AM  3 Ways Pfizer Can Improve Shareholder Value Without Allergan at Motley Fool
05:14AM  Politicians Impede Prosperity
Apr-09-16 09:12AM  9 Drugs That Cost Medicare a Fortune at Motley Fool
Apr-08-16 08:00PM  Stock Mutual Funds Rallied In March Amid Waning Fears About Oil
Apr-07-16 07:00PM  Cramer Remix: Washingtons war on you
02:21PM  What Does the Feds Cautious Move Mean for the Healthcare Sector?
11:59AM  3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead at Motley Fool
10:43AM  Ignore Exelixis, Inc.: Here Are 3 Better Stocks at Motley Fool
10:06AM  Existing Chemotherapy Drugs for Lymphoma
08:07AM  Analysts' Actions -- Bristol-Myers, Coach, IBM, Verizon and More at TheStreet
Apr-06-16 11:45AM  European Commission Approves Bristol-Myers Squibbs Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma Business Wire
11:43AM  Coverage initiated on Bristol-Myers by Societe Generale
11:12AM  European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire
08:49AM  Why the Earnings Streak Will Continue for Bristol-Myers Squibb (BMY)
Apr-05-16 06:36AM  Feds Rosengren Has It Wrong!
Apr-04-16 04:25PM  Bristol-Myers Squibb Buys Into Hot Pharma Segment at Investopedia
04:14PM  Fed Worries, Crude Oil Team Up to Beat Down Wall Street at TheStreet
04:10PM  Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
01:19PM  Jim Cramer: Buy Salesforce, Adobe; Take Your Time on Biotech at TheStreet
05:14AM  Global Events Create Two-Way Markets
Apr-02-16 07:12PM  3 Best Dividend-Paying U.S. Health Care Mutual Funds (VGHCX, BMY) at Investopedia
Apr-01-16 04:15PM  Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc. Business Wire
04:08PM  Market Response to EMA Validation of Opdivo Application
11:52AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma Business Wire
11:07AM  Exploring Pfizers Recent Corporate Developments
11:07AM  Which Segments Will Contribute to Pfizers Growth in 1Q16?
10:34AM  Europe gives green light to first gene therapy for children Reuters
Mar-31-16 05:26PM  Opdivo: Bristol-Myers Squibbs Blockbuster Drug
05:24PM  EMA Validates Opdivos Application for Additional Indications
04:41PM  3 Reasons Investors Can Buy Bristol-Myers Squibb at Motley Fool
09:08AM  Why Actimmune, Horizons Lead Orphan Product, Has Such Huge Potential
Mar-30-16 04:15PM  European Medicines Agency Validates Bristol-Myers Squibbs Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients Business Wire
11:20AM  Jim Cramer -- Avoid Valeant, Shake Shack Costs Way Too Much at TheStreet
11:05AM  Top Dividend-Paying Pharmaceutical Stocks Rated Buy by Analysts at 24/7 Wall St.
08:00AM  Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiologys 65th Annual Scientific Session at noodls
07:50AM  Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiologys 65th Annual Scientific Session at noodls
07:45AM  Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiologys 65th Annual Scientific Session Business Wire
Mar-29-16 03:24PM  [$$] Chinese Market Offers New Life to Many Drugs at The Wall Street Journal
02:37PM  Yellen Says Fed Should Proceed Cautiously
12:06PM  How Mylan Plans to Diversify across Product Lines and Geographies
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM
Blin EmmanuelSVP, Head of CommercializationJul 02Option Exercise0.009510953Jul 07 05:13 PM
Gordon MurdoSVP, Head of Worldwide MarketsJul 01Option Exercise0.002,33502,540Jul 06 07:17 PM
Caldarella Joseph CSVP & ControllerJun 04Sale65.7116,9721,115,22959,284Jun 08 04:17 PM